FDA approves Phase II trial of IkT-001 treatment of MS patients with JCV infection

According to foreign media reports, Inhibikase Medical, an emerging leader in the field of infectious diseases and pharmaceuticals, announced today that it has received FDA approval for the development of its Phase II proof-of-concept trial for lead compound IkT-001. IkT-001 is a host-targeted kinase inhibitor designed to eliminate JC polyoma virus (JCV) infection, which is the causative agent of progressive multifocal leukoencephalopathy (PML). This proof-of-concept trial will be conducted in patients with multiple sclerosis (MS) who received natalizabumab (TYSABRI®), a group of patients with significant risk of potentially fatal progressive multifocal leukoencephalopathy (PML). risk. Only in those patients with chronic or drug-induced immunosuppression, including those diagnosed with clinical AIDS or patients receiving MS, lupus erythematosus, rheumatoid arthritis, leukemia, or lymphoma receiving monoclonal antibodies, JCV progresses to PML,

The four-week, open-label, continuous-dose, phase 2 clinical trial will study the safety of this compound and its antiviral effects against JCV in 48 patients with recurrent MS who received TYSABRI® infusion therapy. In addition to the close examination of the safety and pharmacokinetic properties of IkT-001, this study will also investigate the potential antiviral effects of IkT-001 on JCV. Led by Dr. Jeffrey English of the Center for Major Sclerosis in Atlanta, the study will be conducted at three to five US MS treatment centers.

"For Inhibikase Medical, the launch of this study is a major event. A short period of 23 months of research has led us to promote a new treatment for bacterial and viral infectious diseases into the clinic," said Milton H, President of Inhibikase Medical. . Dr. Werner said, "If IkT-001 is shown to effectively inhibit JCV infection in MS patients receiving TYSABRI®, then more patients with a potential risk of PML will be able to benefit from this therapy by preemptively inhibiting the virus from reaching the brain. IkT-001 Treatment of bacterial and viral infectious diseases through a co-operative mechanism, so the effective results of this phase 2 study can be clarified, and use of the same drug can be used for multiple indications.”

Fresh Red Goji Berry

Banner2

2020101314484118


[Wolfberry" and [goji berry" are synonyms for one of the best-known and admired berries from China, called gou qi or kei tze in Chinese.



The specifications of Dried Goji Berry are distinguished by the number of grains per 50g. The smaller the number of grains per 50g, the larger the grains of each Dried Wolfberry fruit. Generally, the wolfberry with 180 grains per 50g is the least on the market and the most popular.


Goji berries (also known as Wolfberries, Lycium barbarum), have been used in Asian herbal medicine for over 5,000 years and has been regarded as one of the most nutrient-rich foods on earth.


Specifications of Organic Dried Goji Berries:

180 grains/50g,

220 grains/50g,

250 grains/50g,

280 grains/50g,

370 grains/50g,

500 grains/50g,

550 grains/50g,

580 grains/50g, etc.

Red Goji 15


Ways of eating Organic Natural Dried Wolfberry:

Eat directly,

Tea,

Soup,

Chinese medicine formula,

Baking ingredients,

Beverage ingredients


Organic Natural Dried Wolfberry Function:

●Reduce cholesterol.

●Anti-cancer.

●Support normal kidney function.

●Will-being.

●Support healthy liver function.

●Support eye health and improves vision.

●Balance blood pressure and serum sugar.

●Treat sexual dysfunction.

Fresh Red Wolferry,Fresh Organic Red Wolfberry,Chinese Fresh Red Wolfberry,Fresh Red Goji Berry Benefits,Superfood Fresh Red Goji Berry

Ningxia Red Power Goji Co., Ltd. , https://www.redpowergoji.com